{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T14:58:07Z","timestamp":1740149887153,"version":"3.37.3"},"reference-count":42,"publisher":"Wiley","issue":"11","license":[{"start":{"date-parts":[[2017,9,13]],"date-time":"2017-09-13T00:00:00Z","timestamp":1505260800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Int J of Rheum Dis"],"published-print":{"date-parts":[[2018,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Objective<\/jats:title><jats:p>To compare, in real\u2010life conditions, the retention rates of anti\u2010tumor necrosis factor (anti\u2010TNF) treatment (etanercept [ETN], adalimumab [ADA] and infliximab [IFX]) initiated as first\u2010line biotherapy for rheumatoid arthritis (RA) and to evaluate, in case of failure, the switch to another anti\u2010TNF or a non\u2010anti\u2010TNF biological.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Monocentric retrospective cohort including all patients with RA starting a first anti\u2010TNF between 2001 and 2015.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Among the 346 patients analyzed, 201 received ETN, 82 ADA and 63 IFX. The first anti\u2010TNF was interrupted in 151 cases. The retention rates were 82.8%, 67.6%, 46.5%, 28.1% and 22.5% at 1, 2, 5, 10 and 15 years, respectively, with a median retention duration of 52.8 (18.9\u2013136.2) months (ETN: 59.3 [19.1\u2013NA), ADA: 79.9 [19.3\u2013136.2] and IFX: 37.2 [17.5\u2013134.5], <jats:italic>P<\/jats:italic> = 0.49). The predictive factors of discontinuation were active RA (Disease Activity Score of 28 joints \u2013 C\u2010reactive protein [DAS28\u2010CRP] hazards ratio [HR]: 1.22 [1.03\u20131.45]), inflammatory syndrome (erythrocyte sedimentation rate HR: 1.01 [1.0\u20131.02]; CRP HR: 1.00 [1.00\u20131.01]), absence of methotrexate treatment (HR: 0.60 [0.43\u20130.83]), and corticosteroid use (HR: 1.91 [1.31\u20132.78]). The patients who switched to another anti\u2010TNF treatment had an inferior retention than those who switched to a non\u2010anti\u2010TNF treatment (HR: 0.39 [0.17\u20130.87], <jats:italic>P<\/jats:italic> = 0.02).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>In real life, there was no difference in retention among the three anti\u2010TNF agents, and 25% of patients continued them at 15 years. After failure of an anti\u2010TNF, the switch to a non\u2010anti\u2010TNF biotherapy showed better retention.<\/jats:p><\/jats:sec>","DOI":"10.1111\/1756-185x.13156","type":"journal-article","created":{"date-parts":[[2017,9,13]],"date-time":"2017-09-13T11:02:19Z","timestamp":1505300539000},"page":"1924-1932","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Retention rates of adalimumab, etanercept and infliximab as first\u2010line biotherapy agent for rheumatoid arthritis patients in daily practice \u2010 Auvergne experience"],"prefix":"10.1111","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9349-0720","authenticated-orcid":false,"given":"Martin","family":"Soubrier","sequence":"first","affiliation":[{"name":"Rheumatology Department Chu H\u00f4pital Gabriel Montpied Clermont\u2010Ferrand France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruno","family":"Pereira","sequence":"additional","affiliation":[{"name":"Biostatistics Unit (DRCI) Chu H\u00f4pital Gabriel Montpied Clermont\u2010Ferrand France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Frayssac","sequence":"additional","affiliation":[{"name":"Rheumatology Department Chu H\u00f4pital Gabriel Montpied Clermont\u2010Ferrand France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angelique","family":"Fan","sequence":"additional","affiliation":[{"name":"Rheumatology Department Chu H\u00f4pital Gabriel Montpied Clermont\u2010Ferrand France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marion","family":"Couderc","sequence":"additional","affiliation":[{"name":"Rheumatology Department Chu H\u00f4pital Gabriel Montpied Clermont\u2010Ferrand France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandrine","family":"Malochet\u2010Guinamand","sequence":"additional","affiliation":[{"name":"Rheumatology Department Chu H\u00f4pital Gabriel Montpied Clermont\u2010Ferrand France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sylvain","family":"Mathieu","sequence":"additional","affiliation":[{"name":"Rheumatology Department Chu H\u00f4pital Gabriel Montpied Clermont\u2010Ferrand France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zuzana","family":"Tatar","sequence":"additional","affiliation":[{"name":"Rheumatology Department Chu H\u00f4pital Gabriel Montpied Clermont\u2010Ferrand France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne","family":"Tournadre","sequence":"additional","affiliation":[{"name":"Rheumatology Department Chu H\u00f4pital Gabriel Montpied Clermont\u2010Ferrand France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean\u2010Jacques","family":"Dubost","sequence":"additional","affiliation":[{"name":"Rheumatology Department Chu H\u00f4pital Gabriel Montpied Clermont\u2010Ferrand France"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2017,9,13]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200011303432202"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(04)15640-7"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.20217"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.21519"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)61000-4"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.20568"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.091391"},{"key":"e_1_2_6_9_1","first-page":"523","article-title":"Rate of discontinuation and drug survival of biologic therapies in rheumatoid arthritis: a systematic review and meta\u2010analysis of drug registries and health care databases","volume":"55","author":"Souto A","year":"2016","journal-title":"Rheumatology (Oxford)"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.22520"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.105064"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.3109\/03009742.2012.729607"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr.21663"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-015-0776-1"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-203993"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keu158"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2016.13512"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-015-0630-5"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr.22788"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780390105"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2288-2-8"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbspin.2014.02.014"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.27227"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2007.083675"},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbspin.2006.06.011"},{"key":"e_1_2_6_26_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.24463"},{"issue":"12","key":"e_1_2_6_27_1","first-page":"2334","article-title":"Effectiveness, predictive response factors, andsafety of anti\u2010tumor necrosis factor (TNF) therapies in anti\u2010TNF\u2010naive rheumatoidarthritis","volume":"34","author":"Fern\u00e1ndez\u2010Nebro A","year":"2007","journal-title":"J Rheumatol"},{"key":"e_1_2_6_28_1","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.101142"},{"key":"e_1_2_6_29_1","doi-asserted-by":"publisher","DOI":"10.3109\/03009742.2012.762037"},{"key":"e_1_2_6_30_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-204128"},{"key":"e_1_2_6_31_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2010.139774"},{"key":"e_1_2_6_32_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kel149"},{"key":"e_1_2_6_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2013.07.011"},{"key":"e_1_2_6_34_1","doi-asserted-by":"publisher","DOI":"10.1097\/RHU.0000000000000358"},{"key":"e_1_2_6_35_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-204577"},{"key":"e_1_2_6_36_1","first-page":"35","article-title":"Biologic monotherapy in the treatment of rheumatoid arthritis","volume":"9","author":"Detert J","year":"2015","journal-title":"Biologics"},{"key":"e_1_2_6_37_1","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.151014"},{"key":"e_1_2_6_38_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/ken002"},{"key":"e_1_2_6_39_1","doi-asserted-by":"publisher","DOI":"10.3109\/03009742.2011.599073"},{"key":"e_1_2_6_40_1","doi-asserted-by":"publisher","DOI":"10.2152\/jmi.60.77"},{"issue":"6","key":"e_1_2_6_41_1","first-page":"779","article-title":"Drug outcome survey to evaluate anti\u2010TNF treatment in rheumatoid arthritis: an Italian observational study (the DOSE study)","volume":"33","author":"Anecchino C","year":"2015","journal-title":"Clin Exp Rheumatol"},{"key":"e_1_2_6_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbspin.2015.01.021"},{"key":"e_1_2_6_43_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-204714"}],"container-title":["International Journal of Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2F1756-185X.13156","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/1756-185X.13156","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/1756-185X.13156","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/1756-185X.13156","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,10]],"date-time":"2023-09-10T02:40:07Z","timestamp":1694313607000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/1756-185X.13156"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9,13]]},"references-count":42,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2018,11]]}},"alternative-id":["10.1111\/1756-185X.13156"],"URL":"https:\/\/doi.org\/10.1111\/1756-185x.13156","archive":["Portico"],"relation":{},"ISSN":["1756-1841","1756-185X"],"issn-type":[{"type":"print","value":"1756-1841"},{"type":"electronic","value":"1756-185X"}],"subject":[],"published":{"date-parts":[[2017,9,13]]},"assertion":[{"value":"2017-09-13","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}